Eli Lilly’s retatrutide cuts A1C more and doubles weight loss versus Ozempic in Phase 3 head‑to‑head trial
Eli Lilly reported that its investigational triple‑agonist retatrutide lowered hemoglobin A1C by 2.2% and produced 44‑47 lb of weight loss in adults with type 2 diabetes, compared with a 1.8% A1C drop and 21 lb loss on Novo Nordisk’s Ozempic 2 mg. The results came from the 80‑week, open‑label TRANSCEND‑T2D‑2 trial that enrolled 1,298 participants. Executive Vice President Kenneth Custer said the data could shift the treatment paradigm if the drug receives regulatory approval.
Why it matters
The company says the efficacy could reshape diabetes and obesity therapy, potentially opening a new revenue stream once approved (the company’s statement). The trial results also give investors a concrete efficacy benchmark for an upcoming FDA filing expected in early 2027.
Key facts
- 1Retatrutide lowered A1C by an average of 2.2% versus 1.8% for Ozempic at 80 weeks. prnewswire.com
- 2Participants on retatrutide lost an average of 44.3 lb (19.5%) at the 9 mg dose and 47.4 lb (20.9%) at the 12 mg dose, compared with 20.9 lb (9.4%) on Ozempic. prnewswire.com
- 3The trial, TRANSCEND‑T2D‑2, was a Phase 3, randomized, open‑label study of 1,298 adults with type 2 diabetes inadequately controlled with metformin. investor.lilly.com
- 4The primary endpoint was A1C reduction; retatrutide met the primary and all key secondary endpoints. prnewswire.com
- 5Kenneth Custer, Executive Vice President and President of Lilly Cardiometabolic Health, said the data could shift the treatment paradigm for diabetes, obesity and related cardiometabolic conditions. stocktitan.net
- 6Retatrutide is investigational and not yet FDA‑approved; Lilly expects to seek approval in early 2027. abcnews.com
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.